跳至主要内容
临床试验/NCT01951898
NCT01951898Unknown2 期

Effects of Montelukast on Airway Foxp3+ and CTLA4+CD25highCD4+ T Cells in Asthmatics

Kurume University1 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2012年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
入组人数
15
试验地点
1
主要终点
Montelukast will up-regulate airway regulatory T cell in the patients with asthma

研究概览

简要总结

Montelukast is one of anti-inflammatory agents and a good controller for the patients with asthma. The hypothesis of the study is that the Montelukast will have airway anti-inflammatory effects and up-regulated regulatory T cells functions in asthma.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
20 Years 至 50 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • mild status
  • stable status
  • nonsmoker
  • Positive of airway hyperresponsiveness (Methacholine-PC20<16mg/mL)

排除标准

  • taken other asthmatic medications such as oral, injective, and inhaled steroids, leukotriene antagonists, oral, inhaled, and transdermal beta-agonists, theophylline, anti-histamine agents, anti-IgE antibodies and long acting muscarinic receptor antagonists.
  • respiratory tract infections within 4wks
  • moderate to severe other organ disorders
  • active malignancies
  • past histories of side effects of leukotriene antagonists
  • psychological disorders
  • pregnancy or nursing

研究组 & 干预措施

Montelukast

Active Comparator

干预措施: Montelukast (Drug)

Vitamin B6

Sham Comparator

干预措施: Montelukast (Drug)

结局指标

主要结局

Montelukast will up-regulate airway regulatory T cell in the patients with asthma

时间窗: 4wks of treatment period

次要结局

  • Montelukast will improve airway inflammation, lung function and hyperresponsiveness in the patients with asthma(4wks of treatment periods)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Tomotaka Kawayama

MD

Kurume University

研究点 (1)

Loading locations...

相似试验